Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FILRI-CHOP

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChiara PaganiELElisa LucchiniAMA Merli

Discussion

Loading...

Member takes

Overview

Phase II trial shows ibrutinib with R-CHOP improves safety and outcomes in untreated ABC-DLBCL patients.

Key Points

  • This trial aims to evaluate the effectiveness and safety of ibrutinib combined with R-CHOP in high-risk ABC-DLBCL patients.
  • Phase II, multicenter, single-arm trial
  • Enrolling patients aged 18-65 with untreated ABC-DLBCL
  • Initial R-CHOP cycle followed by R-CHOP plus ibrutinib from cycle 2 to 6
  • Ibrutinib maintenance for 18 months post-induction for responders
  • Assessment of COO using NanoString's Lymphoma Subtyping
  • Overall response rate (ORR) of 90.7% after 4 cycles
  • Metabolic complete response (CR) rate of 72% at end of induction
  • Safety profile showed manageable adverse events, including grade 3-4 neutropenia
  • Cardiac events reported in 3 patients, low-grade gastrointestinal and neurological events observed

Cite This Study

Pagani et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfdbhttps://doi.org/10.1182/blood-2025-55
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study2026
  2. 2Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 12012025 · 2 citations
  3. 3Abstract A047: Final analysis of a Phase 1 study of ibrutinib dose-escalation in TEDDI-R with isavuconazole for relapsed or refractory primary DLBCL of the CNS2026
  4. 4Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network2024 · 151 citations
  5. 5Integrating BTK inhibition into R-da-EPOCH for HIV-related DLBCL.2026